-
Three killed in San Diego mosque shooting, both suspects dead
-
Love, lust and gnomes as top UK flower show bursts into bloom
-
Fans of historic DC park wary of Trump plan to 'beautify' city
-
As bee population collapses, US apiarists fear research cuts
-
Lights out for Cuban students as blockade bites
-
Campaigners warn Italy's gutted rape bill could help assailants
-
Libyan ex-prison boss faces ICC war crimes hearing
-
Argentine scientists lay first traps in hantavirus hunt
-
Star of Rome's 'sexy priest' calendar admits: 'I was never a priest'
-
Harry Styles fans to splash over £1 bn on London concerts: Barclays
-
Bolivia protest sees violent clashes, looting in La Paz
-
Trump says held off on new Iran attack, upbeat for agreement
-
Los Angeles World Cup workers vow strike over ICE guarantees
-
Three killed in San Diego mosque shooting, two attackers dead
-
US to screen for Ebola at airports, one American in DR Congo infected
-
Aussie Scott officially set for 100th straight major at US Open
-
Pep Guardiola to leave Man City at end of the season - reports
-
Neymar back in Brazil squad for fourth World Cup
-
Arsenal on the brink of Premier League title after nervy Burnley win
-
Oil rises, global stocks mixed as markets track Iran developments
-
World Cup winner Pavard confirms Marseille exit
-
Trump says holding off on new Iran attack
-
Cuba warns of 'bloodbath' if US attacks; Washington adds sanctions
-
Trump says delaying Iran attack at request of Gulf leaders
-
Cuba warns of 'bloodbath' if US attacks and Washington issues sanctions
-
After mayor's murder, Mexico battles to bring peace
-
Trump admin creates $1.7 bln fund to compensate allies prosecuted under Biden
-
Pelicans name Mosley as coach, two weeks after Magic firing
-
Hyderabad qualify for IPL play-offs along with Gujarat
-
'Girl in the River Main' identified 25 years on, father arrested
-
Musk loses blockbuster OpenAI suit as jury says too late
-
SNC Scandic Coin and Biconomy: Regulated real-world assets meet global trading infrastructure
-
Judge allows gun as evidence in Mangione healthcare exec murder trial
-
First attack on Arab nuclear site sends warning to Gulf, US
-
Oil rises, bond yields weigh on stocks
-
Hormuz tanker traffic edges higher after wartime low
-
Andalusia setback highlights weakness of Spain's ruling Socialists
-
India's Adani to pay $275 mn settlement to US over alleged Iran sanctions violations
-
Middle East tourism pain is Europe's gain
-
UK Labour leadership hopeful reopens Brexit debate
-
PSG's Dembele has treatment for leg issue before Champions League final
-
Spurs must play with 'courage' to seal safety: De Zerbi
-
Hantavirus-hit cruise ship ends deadly voyage
-
Champagne start in Reims for 2028 Tour de France
-
Dogs allowed on new Brigitte Bardot beach in glitzy Cannes
-
Oil prices dip on report of US sanctions relief for Iran during talks
-
Croatia names Modric-led World Cup squad
-
Iran World Cup squad lands in south Turkey for training
-
Mushfiqur ton leaves Pakistan needing record run chase to beat Bangladesh
-
Transport protests hit Kenya over rising fuel prices
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
K.AbuTaha--SF-PST